Research record
Chemotherapy in melanoma
Chemotherapy is not automatically useless, but families should ask why it is being discussed now and what alternatives are being compared.
What this is
Chemotherapy is not automatically useless, but families should ask why it is being discussed now and what alternatives are being compared.
Why it may come up
- selected later-line context
- comparator in trials
- country/access dependent
What not to assume
- Avoid blanket statement that chemotherapy never works.
- Avoid framing chemotherapy as the default modern melanoma pathway.
At a glance
Chemotherapy in melanoma
- Type
- Chemotherapy
- Mutation result
- any
- Where
- Global
- Evidence status
- guideline-category
- Last checked
- 2026-05-20
What we know
- NCI PDQ supports chemotherapy as a melanoma treatment category.
- NCT06008106 uses combination chemotherapy as the comparator against tunlametinib.
What is unclear
- Avoid blanket statement that chemotherapy never works.
- Avoid framing chemotherapy as the default modern melanoma pathway.
Questions to ask
- Why chemotherapy now?
- Is it being used because other options failed, are unavailable, or conflict with trial timing?
- What outcome would show that it is helping?
Related trial leads
NCT06008106
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
Phase III comparator trial after prior immunotherapy; useful for duration-of-response and trial-timing questions.